DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ATRIPLA
➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
All Clinical Trials for Atripla
| Trial ID |
Title |
Status |
Sponsor |
Phase |
Start Date |
Summary |
| NCT00432016 ↗ |
Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV |
Completed |
RFS Pharma, LLC |
Phase 1/Phase 2 |
2007-02-01 |
The purpose of this study is to determine the short term safety, tolerance, and antiviral
effect of zidovudine (AZT) and amdoxovir (AMDX, DAPD) in combination, and whether the dosage
for AZT can be reduced, potentially decreasing side effects, while maintaining antiviral
effects.
Study hypothesis: DADP in combination with AZT is safe and effective, and AZT dosing may be
reduced, resulting in lower levels of AZT-monophosphate associated with toxicity and
maintaining levels of AZT-triphosphate associated with efficacy.
|
| NCT00573001 ↗ |
Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA) |
Completed |
Gilead Sciences |
Phase 3 |
2008-07-01 |
The goal of this trial is to demonstrate that new treatments are as effective as a reference
triple-agent regimen in driving plasma viral load below the detection limit early during
treatment (16 weeks). These simplified treatments involve fewer tablets and intakes,
fixed-dose combinations, and also radically new strategies such as boosted protease
inhibitor and tenofovir.
|
| NCT00573001 ↗ |
Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA) |
Completed |
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba |
Phase 3 |
2008-07-01 |
The goal of this trial is to demonstrate that new treatments are as effective as a reference
triple-agent regimen in driving plasma viral load below the detection limit early during
treatment (16 weeks). These simplified treatments involve fewer tablets and intakes,
fixed-dose combinations, and also radically new strategies such as boosted protease
inhibitor and tenofovir.
|
| >Trial ID |
>Title |
>Status |
>Phase |
>Start Date |
>Summary |
Clinical Trial Conditions for Atripla
Condition Name
| Condition Name for Atripla |
| Intervention |
Trials |
| HIV Infections |
15 |
| HIV |
14 |
| HIV-1 Infection |
6 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Condition MeSH
| Condition MeSH for Atripla |
| Intervention |
Trials |
| HIV Infections |
24 |
| Acquired Immunodeficiency Syndrome |
12 |
| Immunologic Deficiency Syndromes |
7 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Locations for Atripla
Trials by Country
| Trials by Country for Atripla |
| Location |
Trials |
| United States |
134 |
| United Kingdom |
12 |
| Canada |
11 |
| Italy |
8 |
| Germany |
7 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Trials by US State
| Trials by US State for Atripla |
| Location |
Trials |
| North Carolina |
8 |
| California |
8 |
| Massachusetts |
8 |
| New York |
8 |
| Texas |
6 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Progress for Atripla
Clinical Trial Phase
| Clinical Trial Phase for Atripla |
| Clinical Trial Phase |
Trials |
| Phase 4 |
20 |
| Phase 3 |
12 |
| Phase 2/Phase 3 |
3 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Status
| Clinical Trial Status for Atripla |
| Clinical Trial Phase |
Trials |
| Completed |
28 |
| Recruiting |
7 |
| Active, not recruiting |
5 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Sponsors for Atripla
Sponsor Name
| Sponsor Name for Atripla |
| Sponsor |
Trials |
| Gilead Sciences |
19 |
| Merck Sharp & Dohme Corp. |
10 |
| St Stephens Aids Trust |
6 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Sponsor Type
| Sponsor Type for Atripla |
| Sponsor |
Trials |
| Industry |
52 |
| Other |
42 |
| NIH |
5 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
